Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 105

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 105
---
 to investors with respect to our Class A Ordinary Shares (including the amount of any taxes withheld therefrom)
will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated earnings and profits, as
determined under U. S. federal income tax principles.

Business Overview

We are a clinical stage biopharmaceutical
company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through
the co-development of PathsDxTest, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

The Company now focuses all of its efforts on R& D and therefore
no longer performs any therapeutic services. While the Company may commence therapeutic services in the future, as of December 31, 2024
and the date hereof, it only operates in one segment.

Our goal is to develop a broad
range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components
of our strategy for achieving this goal include: (for details of our strategy, See “ Business Overview - Our Strategy”)

  Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas;  

  Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Collaborating with leading academic institutions and CROs;  

  Expanding our in-house pharmaceutical development center;  

  Leveraging our management’s expertise, experience and commercial networks;  

  Obtaining and leveraging government grants to fund project development.  

We have devoted a substantial
portion of the proceeds from our offerings, to our Lead Projects. Our Lead Projects are ALS-4, SACT-1 and PathsDxTest. In
March 2023, we announced that we completed the Pre-IND discussions with the US FDA on ALS-4. With the positive feedback on the overall
development strategy from the US FDA, we are proceeding towards the IND submission of ALS-4. In March 2023, we also announced the completion
of the End of Phase 1 (E